This list is an analysis based on recent market events. It's not an investment recommendation.
OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).
Show more...
FAQ
What is OncoZenge AB stock price today?▼
The current price of ONCOZ.ST is SEK3.58 SEK — it has decreased by -6.28% in the past 24 hours. Watch OncoZenge AB stock price performance more closely on the chart.
What is OncoZenge AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange OncoZenge AB stocks are traded under the ticker ONCOZ.ST.
Is OncoZenge AB stock price growing?▼
ONCOZ.ST stock has fallen by -29.8% compared to the previous week, the month change is a -43.26% fall, over the last year OncoZenge AB has showed a -43.8% decrease.
What is OncoZenge AB market cap?▼
Today OncoZenge AB has the market capitalization of 50.29M
What is OncoZenge AB revenue for the last year?▼
OncoZenge AB revenue for the last year amounts to 2.66M SEK.
What is OncoZenge AB net income for the last year?▼
ONCOZ.ST net income for the last year is -15.94M SEK.
How many employees does OncoZenge AB have?▼
As of September 05, 2026, the company has 1 employees.
In which sector is OncoZenge AB located?▼
OncoZenge AB operates in the Health & Wellness sector.
When did OncoZenge AB complete a stock split?▼
OncoZenge AB has not had any recent stock splits.
Where is OncoZenge AB headquartered?▼
OncoZenge AB is headquartered in Bromma, Sweden.